Evidence map›Paper›PMID 36532038›Full record

ArticleFrontiers in immunology2022

Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis.

Yanhao Liu, Xu Cheng, Xiaona Han, Xi Cheng, Shu Jiang, Yaru Lin, Zhen Zhang, Linlin Lu, Baozhen Qu, Yuxian Chen and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 6 pooled it
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 6 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Review
  9. Article
  10. Article
  11. Mapping the evolution and frontiers ofTranslational lung cancer research · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yanhao LiuDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Xu ChengDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Xiaona HanDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Xi ChengDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Shu JiangDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Yaru LinDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Zhen ZhangDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Linlin LuDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Baozhen QuDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Yuxian ChenDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Xiaotao ZhangDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Affiliated Hospital of Qingdao University · CNQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

​Background: Immunotherapy for lung cancer has been a hot research area for years. This bibliometric analysis aims to present the research trends on lung cancer immunotherapy. Method: On 1 July, 2022, the authors identified 2,941 papers on lung cancer immunotherapy by the Web of Science and extracted their general information and the total number of citations. A bibliometric analysis was carried out to present the research landscape, demonstrate the research trends, and determine the most cited papers (top papers) as well as major journals on lung cancer immunotherapy. After that, recent research hotspots were analyzed based on the latest publications in major journals. Results: These 2,941 papers were cited a total of 122,467 times. "Nivolumab vs. docetaxel in advanced non-squamous non-small-cell lung cancer" published in 2015 by Borghaei H et al. was the most cited paper (5,854 citations). Among the journals, Conclusions: This bibliometric analysis comprehensively and quantitatively presents the research trends and hotspots based on thousands of publications, and further suggests future research directions. Moreover, the results can benefit researchers to select journals and find potential collaborators. This study can help researchers get a comprehensive impression of the research landscape, historical development, and recent hotspots in lung cancer immunotherapy and provide inspiration for further research.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsBibliometricsHumansImmunotherapyPublicationsbibliometric analysisclinical trialsimmunotherapylung cancernivolumabPD1/PDL1pembrolizumabtumor mutation burden

Identifiers

PMID36532038
PMCPMC9751816
OpenAlexW4310490686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.